CDKN2A and ovarian cancer: Elevated stromal p16INK4a expression may correlate with malignancy and tumour aggressiveness, making it a potential marker which can be used as an adjunct to epithelial p16INK4a expression for differentiating malignant ovarian neoplasms from benign or borderline cases [78].